AlzeCure Pharma
STOCKHOLM, SWEDEN / ACCESSWIRE / November 10, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - September 2021 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
"During the third quarter, we received positive data from our Phase I SAD clinical trial with the drug candidate ACD856, which is part of the NeuroRestore platform and which we are developing with a focus on Alzheimer's disease. We also received approval to test higher doses of the compound in the study, which is now underway, and after the end of the quarter we also started our Phase I MAD clinical trial with this compound. Regarding our ACD440 pain project, that belongs to the Painless platform and targets neuropathic pain, we have now submitted a request for a pre-IND meeting to the FDA for a planned Phase II study. We also focused on further developing new compounds in our preclinical pain project, TrkA-NAM, with the aim of choosing a drug candidate for the project in the second half of 2021. Thus we have once again closed the books on yet another positive and very active quarter at AlzeCure."
Martin Jönsson, CEO
Financial information for July - September, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period totaled SEK 0 thousand (0).
- Loss for the period totaled SEK -16,507 thousand (-21,455).
- Earnings per share, basic, totaled SEK -0.44 (-0.57).
- Total assets at the end of the period amounted to SEK 68,299 thousand (138,334).
- Cash and cash equivalents at the end of the period totaled SEK 62,672 thousand (132,976).
Financial information for January - September, 2021
Figures in parentheses refer to the corresponding period of the previous year.
- Net sales during the period amounted to SEK 0 thousand (0).
- The earnings for the period amounted to SEK -55,162 thousand (-53,646).
- Earnings per share before dilution amounted to SEK -1.46 (-1.42).
- Total assets amounted to SEK 68,299 thousand (138,334) at the end of the period.
- Cash and cash equivalents amounted to SEK 62,672 thousand (132,976) at the end of the period.
Significant events during the period January - September, 2021
- The company appointed Associate Professor Märta Segerdahl Storck, MD/PhD, to serve as Chief Medical Officer (CMO). Dr. Segerdahl took up the position on April 1 and is responsible for our clinical development activities. She is also part of AlzeCure's management group.
- In April the company received, slightly ahead of plan, positive and significant efficacy data from the phase Ib clinical trial with the drug candidate ACD440 for neuropathic pain. It was also well tolerated as a topical treatment.
- Eva Lilienberg was elected to serve on AlzeCure's Board of Directors at the Annual General Meeting on May 17. Eva further strengthens the company with her broad international regulatory and commercial experience.
- In July, a new publication on ACD856 was published in the journal Cells, describing the preclinical development of the substances within the NeuroRestore platform and results were presented. (Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction, Cells 2021 Jul23; 10 (8): 1871.)
- New data supporting targeting Trk receptors with ACD856 for treatment of Alzheimer's disease presented at Alzheimer's Association International Conference (AAIC) 2021 on July 26-30 in Denver USA.
- In August the company received approval from the Medical Products Agency to be able to give additional doses of ACD856 in the clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested.
- In August the company received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.
Significant events after the end of the period
- In October the first participant in the clinical phase I study (MAD) with the drug candidate ACD856 was dosed.
- The company presented the potential of the NeuroRestore project in depression at the European College of Neuropsychophamacology (ECNP 2021 on October 2-5 in Lisbon.
The full report is attached as PDF and is available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Attachments
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/672076/AlzeCure-Publishes-its-Interim-Report-for-January-September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
EESystem Triumphs Again: Courts Deem Jason Shurka's Claims “Baseless” and “Futile”31.10.2025 14:25:00 CET | Press release
Judges Continue to Side with Energy Enhancement System as Jason Shurka's Legal Maneuvers Collapse LAS VEGAS, NV / ACCESS Newswire / October 31, 2025 /Energy Enhancement System, LLC ("EES") has achieved another decisive victory in its ongoing effort to defend truth, innovation, and integrity against baseless attacks from Jason Shurka and The Light System, Inc. ("TLS"). The United States District Court for the Eastern District of New York has formally granted EES permission to move forward with its full motion to dismiss - a strong indication that the court recognizes the legal and factual strength of EES's position. Judges in multiple jurisdictions have now described Shurka's filings as "baseless" and "futile," repeatedly returning the cases to the very courts where EES first initiated them - and where EES continues to win. Truth Over Deception The latest decision follows months of extensive filings exposing what EES alleges was a coordinated campaign of misinformation and brand confusi
TruMerit's Peter Preziosi Elected President of the Conference of NGOs in Consultative Relationship With the United Nations30.10.2025 21:00:00 CET | Press release
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 30, 2025 / TruMerit President and CEO Peter Preziosi has been elected President of the Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO. CoNGO | TruMerit Conference of Non-Governmental Organizations in Consultative Relationship with the United Nations, also known as CoNGO and TruMerit CoNGO is an international non-governmental organization founded in 1948 that relates to the United Nations through its General Consultative Status granted by the United Nations Economic and Social Council (ECOSOC). It has 525 member organizations from around the world and 106 associate members. Dr. Preziosi was elected to serve for the 2025-29 term this week at the 28th CoNGO General Assembly, which took place in New York with the virtual participation of organizations from around the world. He succeeds the Rev. Dr. Liberato C. Bautista, the main representative to the UN for the Genera
Polaris Renewable Energy Announces Q3 2025 Results30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the nine and three months ended September 30, 2025. This earnings release should be read in conjunction with the Company's condensed consolidated interim financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. 2025 HIGHLIGHTS Third quarter consolidated energy production totaled 181,235 MWh, representing a 7% increase compared to 168,639 MWh in the same quarter last year. The increase is mainly attributable to the contribution from the Puerto Rican wind farm, acquired on March 3, 2025, which was not part of the portfolio in the comparative quarter of 2024, as well as stronger hydrologi
Polaris Renewable Energy Declares Quarterly Dividend30.10.2025 12:50:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / October 30, 2025 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to announce that its board of directors has declared a quarterly dividend of US$0.15 per common share outstanding. This dividend will be paid on November 21st to shareholders of record at the close of business on November 10th. The dividend is an "eligible dividend" as designated for Canadian federal, provincial, and territorial income tax purposes. The board of directors of Polaris Renewable Energy remains committed to paying a quarterly dividend and will evaluate further dividend increases, as appropriate, going forward. About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America & the Caribbean. We are a high-performing and financially sound contributor to the energy transition. The Compan
Camino and Nittetsu Commence Proprietary Leaching Studies for Growth Opportunities at the Puquios Copper Project in Chile30.10.2025 11:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / October 30, 2025 / :Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce that its joint venture with Nittetsu Mining Co., Ltd. ("Nittetsu") will initiate leaching studies at Nittetsu's metallurgical and chemical facility in Tokyo. These studies aim to assess the scalability of the Puquios Copper Project ("Puquios"or the "Project"). The Puquios mine is planned as a conventional sulphide leaching operation utilizing solvent extraction and electro winning ("SXEW") technology. All permits required for commencement of construction are in place, with mine construction anticipated in the first half of 2026. To support development, Camino and Nittetsu are actively pursuing a debt facility with a Japanese lender that is expected to offer highly competitive terms in the current mining finance environment. The first stage of the Puquios copper mine development is now on a path towards production. The Company is ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom